Welcome to our dedicated page for Pharmacyte Biotech SEC filings (Ticker: PMCB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PharmaCyte Biotech, Inc. (NASDAQ: PMCB) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools that help interpret complex documents. Through Forms 10-K, 10-Q, 8-K, proxy statements, and related exhibits, investors can review how PharmaCyte describes its Cell-in-a-Box live-cell encapsulation technology, its strategic investments in other public companies, and its capital structure.
PharmaCyte’s Form 8-K filings detail material events such as private placements of convertible preferred stock and warrants, cash tender offers for its common stock, and strategic investments in entities including MyMD Pharmaceuticals, Femasys Inc., and TNF Pharmaceuticals (Q/C Technologies, Inc.). These reports also describe terms of preferred stock, warrant exercise prices, conversion features, registration rights agreements, and covenants that affect existing and prospective shareholders.
The company’s proxy materials on Schedule 14A outline special meeting agendas, including proposals to authorize the issuance of common shares underlying preferred stock and warrants under Nasdaq Listing Rule 5635(d), and amendments to the PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan. Filings also cover voting results from special meetings, providing transparency into stockholder approval of equity and financing-related proposals.
Notifications such as the Form 12b-25 (NT 10-Q) explain delays in periodic reports and indicate expected filing timelines. In addition, amended 8-Ks include historical financial statements of investee companies like Q/C Technologies, Inc. and unaudited pro forma condensed combined financial information reflecting PharmaCyte’s investment transactions.
On Stock Titan, these filings are updated in near real time from EDGAR, and AI-generated summaries highlight key points—such as new financing terms, equity issuance limits, insider-relevant provisions, and changes to incentive plans—so readers can quickly understand the implications of lengthy documents without reading every page.
PharmaCyte Biotech, Inc. investors update their ownership report. As of the close of business on December 31, 2025, Mitchell P. Kopin and Intracoastal Capital LLC each report beneficial ownership of 532,254 shares of common stock, or about 4.99% of the class. Daniel B. Asher reports beneficial ownership of 531,086 shares, also about 4.99%.
Their positions are mainly through warrants and preferred stock held by Intracoastal. Multiple warrants and Series H Convertible Preferred Stock include 4.99% blocker provisions, which limit conversions or exercises that would push their beneficial ownership above that threshold. The percentages are calculated using 10,134,160 shares outstanding as of December 16, 2025 plus specified warrant shares.
The reporting persons certify the securities are not held for the purpose of changing or influencing control of PharmaCyte, and the filing reflects that they each own 5 percent or less of the common stock class.
PharmaCyte Biotech, Inc. CEO and President Joshua Silverman reported multiple open-market purchases of the company’s common stock. On January 5, 2026, he bought 30,000 shares at $0.7831 per share. On January 6, 2026, he bought another 30,000 shares at $0.7889 per share, and on January 7, 2026, he bought 40,000 shares at $0.8329 per share.
After these transactions, Silverman directly beneficially owned 416,250 shares of PharmaCyte common stock and indirectly beneficially owned an additional 50,000 shares through JNS Holdings Group LLC.
PharmaCyte Biotech director buys additional shares
Director Jonathan Schechter reported buying a total of 60,000 shares of PharmaCyte Biotech, Inc. common stock in the open market over three consecutive days. He purchased 20,000 shares on January 5, 2026 at
PharmaCyte Biotech, Inc. reports results for the three and six months ended
The company raised
PharmaCyte Biotech, Inc. filed a notice that it will not meet the original deadline for its Quarterly Report on Form 10-Q for the quarterly period ended October 31, 2025. The company says it needs additional time to prepare and review its financial statements to ensure adequate disclosure, and that this delay could not be avoided without unreasonable effort or expense.
Under Rule 12b-25, PharmaCyte expects to file the Form 10-Q no later than the fifth calendar day after the prescribed due date of December 15, 2025. The company indicates that all other required periodic reports over the past 12 months have been filed and that it does not anticipate any significant change in results of operations from the corresponding period of the prior fiscal year in the upcoming report.
PharmaCyte Biotech, Inc. reported equity award activity for director Wayne R. Walker. On 12/12/2025, 37,500 shares of common stock were acquired at $0 per share, and 16,875 shares were disposed of at $1.02 per share to satisfy tax liability upon vesting of restricted stock units, leaving 20,625 shares of common stock directly owned.
Walker also reported receiving 63,233 stock options on 04/25/2025 with an exercise price of $1.22 per share, expiring on 04/24/2035 and covering 63,233 shares of common stock. These options will vest in full on the date of the company’s next annual meeting of stockholders, subject to his continued service, and the company notes the transaction was reported late due to an inadvertent administrative error, not any error of Mr. Walker.
PharmaCyte Biotech, Inc. reported insider equity activity by CEO, President and Director Joshua N. Silverman on 12/12/2025. He acquired 575,000 shares of common stock at $0, increasing his direct holdings.
On the same day, 258,750 shares were disposed of at $1.02 to satisfy the tax liability upon vesting of restricted stock units, and this withholding did not involve an open-market sale. After these transactions, Silverman beneficially owned 316,250 shares directly and 50,000 shares indirectly through JNS Holdings Group LLC.
PharmaCyte Biotech director Jonathan Schechter reported recent equity compensation activity. On 12/12/2025, he acquired 150,000 shares of common stock, with 67,500 shares withheld to cover taxes related to vesting restricted stock units, so the withholding did not involve an open-market sale.
On 04/25/2025, he was also granted stock options covering 63,233 shares of common stock at an exercise price of $1.22 per share, expiring on 04/24/2035. These options are scheduled to vest in full on the date of the company’s next annual meeting of stockholders, subject to his continued service.
PharmaCyte Biotech, Inc., as a reporting person and 10% owner of Q/C Technologies, Inc. (QCLS), reported derivative equity transactions on a Form 4. On 09/04/2025, the reporting person acquired 889,865 shares of Series H Convertible Preferred Stock and related warrants, each ultimately linked to 889,865 shares of common stock. The Series H preferred is convertible into common stock at a conversion price of
PharmaCyte Biotech, Inc. filed an amended Form 8-K to supplement its earlier disclosure about a strategic investment in Q/C Technologies, Inc. The company previously purchased Q/C Series H convertible preferred stock and warrants for an aggregate price of $3,000,000, with the preferred shares convertible into 600,000 Q/C common shares and the warrants exercisable for up to 600,000 additional Q/C common shares. The amendment adds Q/C’s audited financial statements for the years ended December 31, 2024 and 2023, unaudited financials as of June 30, 2025, and unaudited pro forma condensed combined financial information showing how the Transaction would have affected PharmaCyte’s results. The pro forma data are presented for informational and illustrative purposes only and are not projections of future performance.